Showing results (311-320 of 344) with videos related to

Sort By:
Pageof 35
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Neurology|August 28, 2002
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjectsK Buerger, S J Teipel, R Zinkowski, et al.
Palliative Medicine|March 23, 2026
A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)Hanna Hirschinger, Constanze Rémi, Evelyn Jäger, et al.
Nature Medicine|January 25, 2005
Cathepsin L is required for endothelial progenitor cell-induced neovascularizationCarmen Urbich, Christopher Heeschen, Alexandra Aicher, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
The Journal of Experimental Medicine|June 8, 1999
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growthP Schneider, F MacKay, V Steiner, et al.
Annals of Hematology|May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemiaW K Hofmann, G Heil, C Zander, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
British Journal of Haematology|October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Pneumologie (Stuttgart, Germany)|December 17, 2009
[Examples for asbestos-related findings in HRCT - criteria for the assessment of causal relationships in surveillance programmes and medical expert opinion]T Kraus, E Borsch-Galetke, H J Elliehausen, et al.
Pageof 35